NASH
September 3, 2019

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

(Poster, ASCO Annual Meeting, 31 May – 4 June 2019, Abstract #2064)
Read More
PRESS RELEASES
August 2, 2019

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing

Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways  San Mateo, California, August 5, 2019 ­– 3-V Biosciences, a clinical-stage biotechnology company, announced today that…
Read More
PRESS RELEASES
April 30, 2019

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 – 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences…
Read More
PRESS RELEASES
February 13, 2019

Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its…
Read More
NASH
February 13, 2018

Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN

(Presented at the Keystone Symposium on Organ Crosstalk in Obesity and NAFLD, Jan. 21-25, 2018 Keystone, CO, Poster #3028)
Read More
Oncology
October 23, 2017

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis.

(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994)
Read More
Oncology
October 23, 2017

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans.

(Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972)
Read More
PRESS RELEASES
October 16, 2017

3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®

Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class…
Read More
NASH
May 2, 2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment

(Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)
Read More
Oncology
December 12, 2016

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel.

(Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)
Read More